Prosecution Insights
Last updated: November 04, 2026
Application No. 17/957,073

Method of Treating Pemphigus by Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-Enenitrile

Non-Final OA §103
Filed
Sep 30, 2022
Priority
Oct 09, 2019 — provisional 62/913,029 +2 more
Examiner
HUI, SAN MING R
Art Unit
1627
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Principia Biopharma Inc.
OA Round
2 (Non-Final)
60%
Grant Probability
Moderate
2-3
OA Rounds
0m
Est. Remaining
80%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allowance Rate
792 granted / 1328 resolved
At TC average
Strong +20% interview lift
Without
With
+20.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
43 currently pending
Career history
1371
Total Applications
across all art units

Statute-Specific Performance

§101
2.3%
-37.7% vs TC avg
§103
46.9%
+6.9% vs TC avg
§102
7.6%
-32.4% vs TC avg
§112
20.5%
-19.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1328 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under Ex Parte Quayle, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on 6/24/2026 has been entered. Claims 18-19, 43-44, 48-49, 53-58, 62-64, 66, 69-70, 73 are pending. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claim(s) 18-19, 43-44, 48-49, 53-58, 62-64, 66, 69-70, 73 is/are rejected under 35 U.S.C. 103 as being unpatentable over PRN1008 phase II clinical trial record, Version V7, 2018-8-29 (https://clinicaltrials.gov/study/NCT02704429?tab=history&a=7#version-content-panel), hereafter referred as PRN1008 trial, in view of Liang et al., European Journal of Medicinal Chemistry, 2018;151:315-326. PRN1008 trial teaches a phase II clinical trial with the protocol of using PRN1008 to treat pemphigus including patients with relapsing pemphigus (see page 4, Official Title). PRN1008 was administered orally for 12 weeks (see page 6, Brief Summary). PRN1008 trial teaches “The proportion of subjects who are able to achievecontrol of disease activity (CDA) within 4 weeks ofstarting PRN1008 treatment without the need fordoses of prednisone or prednisolone >0.5 mg/kg.” (see page 8). PRN1008 trial does not expressly teach the dosage of PRN1008 as 400mg b.i.d. Liang et al. teaches an overview of Bruton’s tyrosine kinase (BTK) and various different BTK inhibitors including the herein claimed compound, PRN1008 (see page 318, Table 1, for example). Liang et al. teaches the use of BTK inhibitors for treating autoimmune diseases and cancers (see page 318, Table 1). Liang et al. teaches PRN-1008 is a BTK inhibitor in phase II clinical trials for the treatment of pemphigus vulgaris, which successfully completed a phase I study in 2015 (see page 321, col. 2, last paragraph). Liang et al. teaches Phase I studies of PRN-1008 showed that more than 90% target coverage was achieved with a dose of 300 mg, and PRN-1008 was well tolerated at doses up to 600 mg q.d. or 450 mg b.i.d. (see page 322, col. 1, first paragraph). Liang et al. teaches PRN-1008 had been designated an orphan drug in the U.S. for the treatment of pemphigus vulgaris. (see page 322, col. 1, first paragraph). It would have been obvious to one of ordinary skill in the art at the time of filing to employ the herein claimed dosage and dosing regimen. One of ordinary skill in the art would have been motivated to employ the herein claimed dosage and dosing regimen. The optimization of result effect parameters (dosage range, dosing regimens) is obvious as being within the skill of the artisan. The optimization of known effective amounts of known active agents to be administered, is considered well in the competence level of an ordinary skilled artisan in pharmaceutical science, involving merely routine skill in the art. It has been held that it is within the skill in the art to select optimal parameters, such as amounts of ingredients, in a composition in order to achieve a beneficial effect. See In re Boesch, 205 USPQ 215 (CCPA 1980). It is also noted that “[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). Since the daily dosage taught in the cited prior art encompasses that recited in the claims (600-900mg daily in the prior art vs 800 mg daily recited I the claims), adjustment of dosage and/or dosing regimen would be considered obvious. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SAN MING R HUI whose telephone number is (571)272-0626. The examiner can normally be reached Mon - Fri 9:30-5:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney Klinkel can be reached at 571-270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SAN MING R HUI/Primary Examiner, Art Unit 1627
Read full office action

Prosecution Timeline

Show 2 earlier events
Apr 09, 2025
Response Filed
Oct 10, 2025
Request for Continued Examination
Oct 14, 2025
Response after Non-Final Action
Jan 22, 2026
Request for Continued Examination
Jan 28, 2026
Response after Non-Final Action
Jun 26, 2026
Request for Continued Examination
Jun 26, 2026
Response after Non-Final Action
Sep 10, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778967
METHODS OF TREATING TESTOSTERONE DEFICIENCY
3y 2m to grant Granted Nov 03, 2026
Patent 12780805
NITROPHENYL-ACRYLAMIDES AND USES THEREOF
3y 0m to grant Granted Nov 03, 2026
Patent 12780829
ULK1 AND ULK2 INHIBITORS
2y 4m to grant Granted Nov 03, 2026
Patent 12773392
ORAL THIN FILM COMPRISING A PVA-TRIS BUFFER LAYER
3y 3m to grant Granted Oct 27, 2026
Patent 12765552
POLYSUBSTITUTED NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES, PREPARATION METHOD AND USE THEREOF
3y 1m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
60%
Grant Probability
80%
With Interview (+20.1%)
2y 11m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1328 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month